Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

by Wei, Ziwen , De Angelis, Flávia , Jennens, Ross R , Gray, Jhanelle E , Clingan, Philip , Reck, Martin , Vida, John , Boyer, Michael , Peled, Nir , Hui, Rina , Rodríguez-Abreu, Delvys , Novello, Silvia , Gandhi, Leena , Esteban, Emilio , Garon, Edward B , Powell, Steven F , Gadgeel, Shirish , Rubio-Viqueira, Belén , Kurata, Takayasu , Cheng, Susanna Y.-S , Felip, Enriqueta , Raftopoulos, Harry , Pietanza, M. Catherine , Hochmair, Maximilian J , Domine, Manuel , Grossi, Francesco , Yang, Jing , Garassino, Marina C , Bischoff, Helge G

in Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - secondary / Chemotherapy / Cytotoxicity / Death / Disease-Free Survival / Double-Blind Method / Epidermal growth factor receptors / Female / Follow-Up Studies / Hospitals / Humans / Immunotherapy / Kaplan-Meier Estimate / Laboratories / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Male / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Mutation / Non-small cell lung carcinoma / Patients / PD-L1 protein / Pembrolizumab / Platinum / Response rates / Targeted cancer therapy

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

2018

Confirm

Do you wish to request the book?

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Wei, Ziwen,

De Angelis, Flávia,

Jennens, Ross R,

Gray, Jhanelle E,

Clingan, Philip,

Reck, Martin,

Vida, John,

Boyer, Michael,

Peled, Nir,

Hui, Rina,

Rodríguez-Abreu, Delvys,

Novello, Silvia,

Gandhi, Leena,

Esteban, Emilio,

Garon, Edward B,

Powell, Steven F,

Gadgeel, Shirish,

Rubio-Viqueira, Belén,

Kurata, Takayasu,

Cheng, Susanna Y.-S,

Felip, Enriqueta,

Raftopoulos, Harry,

Pietanza, M. Catherine,

Hochmair, Maximilian J,

Domine, Manuel,

Grossi, Francesco,

Yang, Jing,

Garassino, Marina C,

Bischoff, Helge G

2018

Overview

The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ Antineoplastic Agents, Immunological - adverse effects

/ Antineoplastic Agents, Immunological - therapeutic use